Maria Calbacho

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Timing of Allogeneic Hematopoietic Cell Transplantation After Inotuzumab Ozogamicin Influences Sinusoidal Obstruction Syndrome and Survival in Relapsed/Refractory B-ALL.

Timing of Allogeneic Hematopoietic Cell Transplantation After Inotuzumab Ozogamicin Influences Sinusoidal Obstruction Syndrome and Survival in Relapsed/Refractory B-ALL.

Journal: Transplantation and cellular therapy

Published: June 15, 2026

Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies.

Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies.

Journal: Open forum infectious diseases

Published: April 28, 2026

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica

Published: March 10, 2026

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Journal: Journal for immunotherapy of cancer

Published: February 25, 2026

Incidence proportion and divergent performance of risk factors for carbapenem-resistant Gram-negative bacteria bloodstream infections across haematological cohorts.

Incidence proportion and divergent performance of risk factors for carbapenem-resistant Gram-negative bacteria bloodstream infections across haematological cohorts.

Journal: JAC-antimicrobial resistance

Published: January 21, 2026

Case Report: Durable remission of intraocular mantle cell lymphoma after CD19 CAR-T therapy.

Case Report: Durable remission of intraocular mantle cell lymphoma after CD19 CAR-T therapy.

Journal: Frontiers in immunology

Published: January 12, 2026

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies.

Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies.

Journal: Frontiers in oncology

Published: December 01, 2025

Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy.

Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy.

Journal: Transplantation and cellular therapy

Published: November 12, 2025

Spanish Real-World Experience with Belumosudil for Chronic Graft-versus-Host Disease after 2 or More Prior Lines of Therapy.

Spanish Real-World Experience with Belumosudil for Chronic Graft-versus-Host Disease after 2 or More Prior Lines of Therapy.

Journal: Transplantation and cellular therapy

Published: November 12, 2025

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 13, 2025

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Journal: Blood advances

Published: August 20, 2025

Showing 1-12 of 72

Last Updated: 09/26/2026